论文部分内容阅读
据推测青光眼将成为继白内障后第二位致盲性眼病,目前有药物和外科治疗两种方法,但主要是外科治疗随着对青光眼发病机制的不断研究。抗青光眼药物也有了飞速发展,人们试图寻找这样的药物。1)能显著降低眼压。2)付作用小。3)能改善眼部尤其是视乳头血流。4)能预防视野缺损的进展。从而使病人不需手术治疗而病情得以控制。 β-受体阻滞剂:噻吗心安、贝特舒、贝他根、美特朗、降眼压效果明确,对视乳头血流的影响研究较多。但结果各不相同,还未有定论,长期应用对视野的保持作用有待进一步证实。应用该药品其眼部付作用以刺激感,烧灼感最常见,还
It is speculated that glaucoma will become the second blinding eye disease after cataract. There are currently two methods of drug and surgical treatment, but mainly surgical treatment with the continuous study of the pathogenesis of glaucoma. Anti-glaucoma drugs have also been rapid development, people are trying to find such drugs. 1) can significantly reduce intraocular pressure. 2) Pay a small role. 3) can improve the eye especially the optic nerve blood flow. 4) can prevent the progress of visual field defect. So that patients without surgery and disease can be controlled. β-blockers: timolol, Betheshu, Betal root, the United States Trand, clear intraocular pressure effect, the impact on the optic nerve blood flow more. However, the results vary, but there is no final conclusion. The long-term application of the preservation of the field of vision needs to be further confirmed. The application of the drug eye to pay to stimulate the sense of role, the most common burning, but also